Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.

Fraga, Montserrat; Fournier, Nicolas; Safroneeva, Ekaterina; Pittet, Valérie; Godat, Sébastien; Straumann, Alex; Nydegger, Andreas; Vavricka, Stephan R; Moradpour, Darius; Schoepfer, Alain M (2017). Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. European journal of gastroenterology & hepatology, 29(1), pp. 91-97. Lippincott Williams & Wilkins 10.1097/MEG.0000000000000747

Preview	Text Fraga EurJGastroenterolHepatol 2017.pdf - Published Version Available under License Publisher holds Copyright. Download (225kB) | Preview
Preview	Text Fraga EurJGastroenterolHepatol 2017_postprint.pdf - Accepted Version Available under License Publisher holds Copyright. Download (841kB) | Preview

BACKGROUND AND AIM

Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD). We aimed to assess the prevalence of PSC in the Swiss Inflammatory Bowel Disease Cohort Study, to identify associated risk factors, and to describe the long-term evolution.

PATIENTS AND METHODS

Data of patients enrolled into the Swiss Inflammatory Bowel Disease Cohort Study were analyzed. Logistic regression modeling was performed to identify risk factors for PSC.

RESULTS

Among 2744 patients [1188 ulcerative colitis (UC); 1556 Crohn's disease (CD)], 57 had PSC (48 UC-PSC, nine CD-PSC). The prevalence of PSC was higher in UC compared with CD (4.04 vs. 0.58%, P<0.001). We identified the following significant independent risk factors for PSC in patients with UC: male sex [odds ratio (OR) 2.771, P=0.022], pancolitis (OR 2.855, P=0.011), nonsmoker at diagnosis (OR 9.253, P=0.030), and a history of appendicectomy (OR 4.114, P=0.019). During a median follow-up time of 74.8 months, four (7.0%) of PSC patients developed cholangiocarcinoma, six (10.5%) underwent liver transplantation, and five (8.8%) died. Survival of IBD-PSC patients was significantly worse compared with IBD patients without PSC (P=0.001). UC-PSC patients developed significantly more frequently colorectal cancer compared with UC patients without PSC (2/48 vs. 9/1440, P=0.017).

CONCLUSION

Approximately 4% of UC patients and 0.6% of CD patients had PSC. Male sex, pancolitis, nonsmoker status, and a history of appendicectomy were significantly associated with PSC. PSC is associated with considerable morbidity and mortality in the long term.

Interest & Impact

Downloads

452 since deposited on 05 Sep 2017
128 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item